G20

Parkinson's disease

## Overview of Parkinson's Disease (G20) Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder primarily affecting the motor system, but also presenting with a wide range of non-motor symptoms. It is the second most common neurodegenerative disease after Alzheimer's disease, typically manifesting in individuals over the age of 60, though early-onset forms can occur. The ICD-10 code G20 specifically identifies Parkinson's disease. ### Pathophysiology The cardinal pathological hallmark of Parkinson's disease is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain. These neurons produce dopamine, a neurotransmitter critical for motor control, motivation, and reward. The loss of these neurons leads to a significant reduction of dopamine in the striatum, disrupting the finely tuned balance of the basal ganglia circuits and resulting in the characteristic motor symptoms. Another defining pathological feature is the presence of Lewy bodies, which are abnormal intracytoplasmic aggregates primarily composed of alpha-synuclein protein, within surviving neurons in various brain regions, including the SNpc. The exact mechanisms by which alpha-synuclein aggregates contribute to neurodegeneration are still under investigation, but they are thought to impair neuronal function, activate inflammatory responses, and contribute to cell death. The disease process often begins years before motor symptoms become apparent, affecting other areas like the olfactory bulb and enteric nervous system, explaining common prodromal non-motor symptoms. ### Clinical Presentation Parkinson's disease presents with a classic tetrad of motor symptoms, often remembered by the acronym TRAP: Tremor: Typically a resting tremor, often described as "pill-rolling," affecting one limb initially and spreading. It tends to diminish with voluntary movement. Rigidity: Stiffness or inflexibility of the limbs or trunk, which can be constant (lead-pipe rigidity) or intermittent (cogwheel rigidity), often elicited by passive range of motion. Akinesia/Bradykinesia: Slowness of movement and difficulty initiating movement. This is a core symptom and manifests as reduced facial expression (hypomimia or masked facies), reduced arm swing, micrographia (small handwriting), dysphagia (difficulty swallowing), and dysarthria (slurred speech). Gait may be shuffling with reduced stride length. Postural Instability: Impaired balance and coordination, leading to an increased risk of falls, especially in later stages. Beyond motor symptoms, non-motor symptoms are highly prevalent and can precede motor symptoms by many years. These include, but are not limited to, anosmia (loss of smell), chronic constipation, REM sleep behavior disorder (RBD), depression, anxiety, fatigue, pain, cognitive impairment (which can progress to dementia), and autonomic dysfunction (e.g., orthostatic hypotension, urinary urgency, sexual dysfunction). The presence and severity of these non-motor symptoms significantly impact quality of life. ### Diagnostic Criteria The diagnosis of Parkinson's disease is primarily clinical, based on a detailed history and neurological examination. There are no definitive biomarkers or imaging tests for idiopathic PD. Key diagnostic criteria, such as those from the Movement Disorder Society (MDS), emphasize: Parkinsonism: Presence of bradykinesia plus either resting tremor or rigidity. Exclusion Criteria: Ruling out other forms of parkinsonism (e.g., drug-induced parkinsonism, atypical parkinsonism, vascular parkinsonism). Supportive Criteria: Features like clear response to levodopa therapy, presence of dyskinesia (levodopa-induced), and asymmetric onset of motor symptoms. Imaging studies like DaTscan (dopamine transporter scan) can support the diagnosis by showing reduced dopamine transporter uptake in the striatum, but cannot differentiate PD from other synucleinopathies or atypical parkinsonism. Genetic testing is available for specific familial forms but is not routinely used for idiopathic PD diagnosis. ### Standard of Care Management of Parkinson's disease is symptomatic and multidisciplinary, as there is currently no cure to halt or reverse the neurodegeneration. Pharmacological Treatment: Levodopa: The most effective drug for motor symptoms, converted to dopamine in the brain. Often combined with carbidopa/benserazide to reduce peripheral side effects. Dopamine Agonists: (e.g., pramipexole, ropinirole) Mimic dopamine in the brain and can be used alone or with levodopa, especially in early disease or to reduce levodopa-induced dyskinesia. MAO-B Inhibitors: (e.g., selegiline, rasagiline) Reduce the breakdown of dopamine. COMT Inhibitors: (e.g., entacapone, opicapone) Prolong the effect of levodopa. Amantadine: May help with dyskinesia and mild motor symptoms. Anticholinergics: (e.g., trihexyphenidyl) Can be used for tremor, but often limited by side effects in older adults. Non-Pharmacological Interventions: Physical therapy, occupational therapy, and speech therapy are crucial for maintaining mobility, independence, and communication. Regular exercise is highly encouraged to improve motor function, balance, and overall well-being. Nutritional counseling may address dysphagia and constipation. Surgical Interventions: Deep Brain Stimulation (DBS) is an option for select patients with advanced PD who experience severe motor fluctuations and dyskinesia refractory to optimal medical therapy. It involves implanting electrodes in specific brain regions to deliver electrical impulses, improving motor control. Treatment plans are highly individualized, tailored to the patient's symptoms, age, and disease progression. Regular follow-up with a neurologist specializing in movement disorders is essential for optimal management. The goal is to improve quality of life by managing both motor and non-motor symptoms effectively.

Clinical Symptoms

  • Resting tremor (e.g., pill-rolling tremor)
  • Bradykinesia (slowness of movement)
  • Rigidity (cogwheel or lead-pipe)
  • Postural instability (impaired balance, increased falls)
  • Micrographia (small handwriting)
  • Hypomimia (reduced facial expression, masked facies)
  • Shuffling gait with reduced arm swing
  • Dysarthria (slurred or soft speech)
  • Dysphagia (difficulty swallowing)
  • Anosmia or hyposmia (reduced sense of smell)
  • Constipation
  • REM sleep behavior disorder (RBD)
  • Depression
  • Anxiety
  • Cognitive impairment (ranging from mild to dementia)
  • Fatigue
  • Orthostatic hypotension
  • Sialorrhea (drooling)
  • Sexual dysfunction
  • Pain
  • Urinary urgency or frequency
  • Dystonia (sustained muscle contractions)

Common Causes

  • Idiopathic Parkinson's disease (most common, exact cause unknown)
  • Degeneration of dopaminergic neurons in the substantia nigra pars compacta
  • Formation of Lewy bodies (alpha-synuclein aggregates) within neurons
  • Genetic factors (mutations in genes such as SNCA, LRRK2, PRKN, PINK1, DJ-1, GBA)
  • Advanced age (major risk factor)
  • Environmental factors (e.g., exposure to certain pesticides like rotenone and paraquat, solvent exposure, heavy metals)
  • Family history of Parkinson's disease

Documentation & Coding Tips

Document the specific motor and non-motor symptoms of Parkinson's disease, including their severity and impact on daily activities. Distinguish between tremor-dominant and postural instability/gait difficulty (PIGD) subtypes if clinically relevant.

Example: Patient presents with idiopathic Parkinson's disease, diagnosed 5 years ago, currently exhibiting moderate bradykinesia and rigidity, primarily right-sided, significantly impacting dressing and ambulation. Also reports severe REM sleep behavior disorder and mild cognitive impairment. UPDRS III score 28. Managed on Carbidopa/Levodopa with good response. The documented severity and impact on ADLs support medical necessity for ongoing complex management. The presence of documented cognitive impairment (HCC risk) and the specific symptom profile contribute to accurate risk adjustment.

Billing Focus: Specificity of symptoms (e.g., bradykinesia, rigidity, tremor), laterality (if applicable), and clear statement of impact on ADLs justify higher E/M levels and support medical necessity. Mentioning 'idiopathic' clarifies the primary nature of G20.

Clearly document any complications associated with Parkinson's disease, such as falls, dyskinesias, motor fluctuations (on/off phenomena), or psychosis, and their relationship to the underlying condition or medication regimen.

Example: Patient with G20 Parkinson's disease experiencing increasing 'off' periods (motor fluctuations) despite optimized levodopa regimen, leading to significant gait instability and one fall in the past month without injury. Also noted mild levodopa-induced dyskinesia in the afternoon. These complications are directly related to the progression of Parkinson's disease and its treatment. The documented 'falls' and 'dyskinesia' indicate increased severity and complexity, supporting risk adjustment for a higher level of care and increased resource needs.

Billing Focus: Documenting complications (e.g., R25.8 for dyskinesia, R29.810 for falls) as 'due to Parkinson's' or 'related to Parkinson's treatment' provides a clear link, supporting medical necessity for interventions and higher E/M service complexity. This also justifies medication adjustments or further diagnostic workup.

Distinguish between Parkinson's disease (G20) and other forms of Parkinsonism (e.g., secondary Parkinsonism, atypical Parkinsonism, drug-induced Parkinsonism). If the diagnosis is unclear, document 'suspected Parkinson's disease' with a plan for further evaluation.

Example: Patient presenting with symmetrical bradykinesia and rigidity, poor response to levodopa, and early autonomic dysfunction. Differential diagnosis includes Atypical Parkinsonism (e.g., PSP, MSA). Rule out Drug-Induced Parkinsonism (G21.19) due to recent antipsychotic use. Plan: Refer to Neurology for DaTscan and further evaluation to confirm G20 vs. G21. The patient's complex presentation and need for specialty consultation to differentiate Parkinson's from atypical forms indicate a high level of medical decision making.

Billing Focus: Accurate differential diagnosis documentation is crucial. Coding G20 for idiopathic Parkinson's disease requires clear clinical evidence. If drug-induced, G21.1X should be used. Using 'rule out' codes (e.g., R25.8, R26.89 for symptoms) until a definitive diagnosis is made, or documenting the suspected conditions, supports the medical necessity for diagnostic tests and consultations.

Document the patient's response to treatment, including medication names, dosages, and any side effects. Note compliance and adherence to the treatment plan.

Example: Patient with G20, stable on Carbidopa/Levodopa 25/100mg QID and Entacapone 200mg with each levodopa dose. Reporting good motor control with mild, manageable peak-dose dyskinesia. Patient is compliant with medication regimen. Discussed potential for dose titration if motor fluctuations worsen. This detailed medication management, response, and side effects are critical for ongoing care planning. Documenting 'stable' indicates ongoing management of a chronic condition.

Billing Focus: Explicitly listing medications, dosages, and patient response supports complex medication management (e.g., for E/M coding) and demonstrates ongoing active treatment for a chronic condition. Documenting side effects and management strategies further justifies the medical decision-making level.

Include documentation of any non-pharmacological interventions or referrals, such as physical therapy, occupational therapy, speech therapy, or psychological counseling, and their effectiveness.

Example: Patient with G20 continues weekly physical therapy (PT) for gait training and balance exercises; reported improved stability per PT notes. Also referred to occupational therapy (OT) to address fine motor deficits impacting meal preparation. PT is crucial for managing motor symptoms and preventing falls. The referral for OT highlights the progression and ongoing functional impact of G20. These interventions are integral to comprehensive care.

Billing Focus: Documenting referrals and the patient's engagement in multidisciplinary care supports the overall complexity of care provided and reinforces the medical necessity for comprehensive management. It can also justify higher E/M service levels due to coordination of care.

Relevant CPT Codes

Related Diagnoses

Hierarchy